Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Liabilities and Shareholders Equity (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $594.8 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 10.02% to $594.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 billion through Dec 2025, up 0.69% year-over-year, with the annual reading at $594.8 million for FY2025, 10.02% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $594.8 million at Nuvation Bio, down from $601.6 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $657.1 million in Q1 2023, with the low at $492.5 million in Q1 2025.
  • Average Liabilities and Shareholders Equity over 3 years is $600.6 million, with a median of $607.3 million recorded in 2024.
  • Peak annual rise in Liabilities and Shareholders Equity hit 10.02% in 2025, while the deepest fall reached 19.68% in 2025.
  • Over 3 years, Liabilities and Shareholders Equity stood at $621.5 million in 2023, then dropped by 13.01% to $540.6 million in 2024, then increased by 10.02% to $594.8 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $594.8 million, $601.6 million, and $647.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.